Navigation Links
Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Date:2/15/2011

are encouraged by the initial trial results, and look forward to completion of this trial in the near future."

About iCONThe International Congress for Endovascular Specialists annual meeting is presented by the Arizona Heart Foundation and the International Society of Endovascular Specialists.  The meeting provides a multidisciplinary forum for the discussion of a wide range of endovascular topics including acute stroke, carotid artery disease, structural heart disease, heart failure therapies, thoracic and abdominal aortic pathologies, and peripheral vascular disorders. There are also concurrent cardiac sessions addressing chronic heart failure, arrhythmias, and percutaneous valve replacement.  The meeting is being held from February 13-17, 2011 in Scottsdale, Arizona.  More information is available at www.iconmeeting.org.  

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA).  AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of E
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
8. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
9. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
10. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
11. Endologix Reports 30% Third Quarter 2010 Revenue Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... 11, 2011 Tonight,s "Dan Rather Reports" examines ... of antibiotics. Every year, more than 90,000 Americans ... antibiotic-resistant infections, caused directly by the overuse of ... $35 billion a year.  In tonight,s program, Dan ...
... 2011 WebMD Health Corp. (Nasdaq: WBMD ) ... million aggregate principal amount of 2.50% Convertible Notes due 2018 ... the exercise in full of the initial purchaser,s over-allotment option). ... to Rule 144A under the Securities Act of 1933.   ...
Cached Medicine Technology:Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 2Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 3Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 4WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... have alerted the public about toxic carrot juice supplied ... Canadians// due to the contamination caused by the botulism ... by Bolthouse Farms, nearly 10 Toronto Businesses continued to ... States nearly four were hospitalized after consuming the juice, ...
... may be governed by her ovaries according to a new ... Claire// showed that women put more time and effort into ... a woman’s clothes and makeup affected at that time of ... men and each other alter as well. ,Study's ...
... dengue fever grips the country, another viral disease chikungunya ... //have been reported across nine states. ,Though Delhi ... worst hit is Karnataka with over 756,028 suspected cases ... ,Maharashtra has 262,595 suspected and 679 confirmed cases. ...
... indeed a wake-up call to the food and drug watchdog, ... in the market. This has been put forth vociferously by ... advisory panel. ,A report enabled by The Institute ... the FDA with more manpower, finance and authority to be ...
... For Health Technologies Inc., makers of IntelliFill i.v.?, ... IV medications in syringes//, announced today that Children’s ... producing over three million syringes using the IntelliFill ... October 2002. The hospital’s inpatient pharmacy is currently ...
... Dr Mukesh Haikerwal, said today the Government must make ... to be truly effective in meeting the needs of ... were announced today by the Prime Minister, and the ... care. ,While the AMA is generally pleased ...
Cached Medicine News:Health News:Women’s Fashion Sense Linked to Her Ovulatio 2Health News:Medical Center Tops 3 Million IV Syringes Using IntelliFill i.v. Robotics 2Health News:Mental Health Package Regrettably Undervalues the Role of the GP 2
... True/Flex Upper Extremity Intramedullary Rod System offers ... to conventional methods of rodding and plating. ... at the fracture site and enhanced healing4 ... to be easily inserted into the canal. ...
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The True/Fix Compression Hip Screw System offers a wide variety of plate and screw sizes available....
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
Medicine Products: